BACKGROUND: In past decade, the treatment of gastric adenocarcinoma has evolved as a result of the publication of two seminal randomized controlled trials. We aimed to examine treatment trends for resectable gastric cancer (stage I-III) using the National Cancer Data Base (NCDB). Our hypothesis was that the use of chemotherapy and chemoradiotherapy in addition to surgery for the treatment of gastric adenocarcinoma has increased from 2000 to 2009. METHODS: Patients diagnosed with stage I-III gastric adenocarcinoma between 2000 and 2009 were selected from the NCDB Hospital Comparison Benchmark Reports. Attention was paid to the initial treatment regimen and data on hospital setting were collected and analyzed. The Cochran-Armitage test for trend was used to assess changes in treatment over time. RESULTS: A total of 50,778 patients with stage I-III gastric adenocarcinoma were included in the analysis. Between 2000 and 2009, the use of surgery alone decreased significantly across all three stages at both teaching hospitals and community hospitals (p < 0.0001 for all cases). In the same period, the use of chemotherapy in addition to surgery increased significantly across all three stages and at both hospital settings (p < 0.0001 for all cases). Surgery plus chemoradiotherapy increased for stage I-III disease at community hospitals (p < 0.05 for all) but only increased significantly for stage II disease at teaching hospitals (p < 0.01). Incidentally, nonsurgical treatment increased across all three stages at both hospital settings (p < 0.001 for all cases). CONCLUSIONS: Data from the NCDB from 2000 to 2009 demonstrate that there has been an increasing use of chemotherapy in addition to surgery for resectable gastric cancer.
BACKGROUND: In past decade, the treatment of gastric adenocarcinoma has evolved as a result of the publication of two seminal randomized controlled trials. We aimed to examine treatment trends for resectable gastric cancer (stage I-III) using the National Cancer Data Base (NCDB). Our hypothesis was that the use of chemotherapy and chemoradiotherapy in addition to surgery for the treatment of gastric adenocarcinoma has increased from 2000 to 2009. METHODS:Patients diagnosed with stage I-III gastric adenocarcinoma between 2000 and 2009 were selected from the NCDB Hospital Comparison Benchmark Reports. Attention was paid to the initial treatment regimen and data on hospital setting were collected and analyzed. The Cochran-Armitage test for trend was used to assess changes in treatment over time. RESULTS: A total of 50,778 patients with stage I-III gastric adenocarcinoma were included in the analysis. Between 2000 and 2009, the use of surgery alone decreased significantly across all three stages at both teaching hospitals and community hospitals (p < 0.0001 for all cases). In the same period, the use of chemotherapy in addition to surgery increased significantly across all three stages and at both hospital settings (p < 0.0001 for all cases). Surgery plus chemoradiotherapy increased for stage I-III disease at community hospitals (p < 0.05 for all) but only increased significantly for stage II disease at teaching hospitals (p < 0.01). Incidentally, nonsurgical treatment increased across all three stages at both hospital settings (p < 0.001 for all cases). CONCLUSIONS: Data from the NCDB from 2000 to 2009 demonstrate that there has been an increasing use of chemotherapy in addition to surgery for resectable gastric cancer.
Authors: Karen L Sherman; Ryan P Merkow; Karl Y Bilimoria; C Edward Wang; Mary F Mulcahy; Al B Benson; David J Bentrem Journal: Ann Surg Oncol Date: 2012-08-14 Impact factor: 5.344
Authors: J S Macdonald; S R Smalley; J Benedetti; S A Hundahl; N C Estes; G N Stemmermann; D G Haller; J A Ajani; L L Gunderson; J M Jessup; J A Martenson Journal: N Engl J Med Date: 2001-09-06 Impact factor: 91.245
Authors: Christoph Schuhmacher; Stephan Gretschel; Florian Lordick; Peter Reichardt; Werner Hohenberger; Claus F Eisenberger; Cornelie Haag; Murielle E Mauer; Baktiar Hasan; John Welch; Katja Ott; Arnulf Hoelscher; Paul M Schneider; Wolf Bechstein; Hans Wilke; Manfred P Lutz; Bernard Nordlinger; Eric Van Cutsem; Jörg R Siewert; Peter M Schlag Journal: J Clin Oncol Date: 2010-11-08 Impact factor: 44.544
Authors: Natalie G Coburn; Ulrich Guller; Nancy N Baxter; Alex Kiss; Jolie Ringash; Carol J Swallow; Calvin H L Law Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-01 Impact factor: 7.038
Authors: David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua Journal: N Engl J Med Date: 2006-07-06 Impact factor: 91.245
Authors: Rhami Khorfan; Cary Jo R Schlick; Anthony D Yang; David D Odell; David J Bentrem; Ryan P Merkow Journal: J Gastrointest Surg Date: 2019-11-20 Impact factor: 3.452
Authors: Jason D Wright; Benjamin Margolis; June Y Hou; William M Burke; Ana I Tergas; Yongmei Huang; Jim C Hu; Cande V Ananth; Alfred I Neugut; Dawn L Hershman Journal: Am J Obstet Gynecol Date: 2016-02-11 Impact factor: 8.661
Authors: Xuguang Chen; Jennifer R Eads; John B Ammori; Aryavarta M Kumar; Tithi Biswas; Jennifer A Dorth Journal: Curr Oncol Rep Date: 2015-04 Impact factor: 5.945
Authors: Kelly A Stahl; Elizabeth J Olecki; Matthew E Dixon; June S Peng; Madeline B Torres; Niraj J Gusani; Chan Shen Journal: Curr Oncol Date: 2020-12-24 Impact factor: 3.677